PCS
NBIX icon

Private Client Services’s Neurocrine Biosciences NBIX Stock Holding History

Private Client Services’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$532K Sell
3,156
-9,310
-75% -$1.38M 0.14% 128
2026
Q1 		$1.64M Buy
+12,466
New +$1.65M 0.49% 48

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Private Client Services's NBIX Position: Q2 2026 in Review

Private Client Services reduced its Neurocrine Biosciences (NBIX) stake by 75% in Q2 2026, selling an estimated $1.38M and leaving 3,156 shares worth $532K. The position accounts for 0.14% of the portfolio, ranked #128.

Private Client Services first reported a position in NBIX in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.64M in Q1 2026. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Private Client Services held 3,156 shares of Neurocrine Biosciences worth $532K as of Q2 2026.
  • Private Client Services sold 9,310 Neurocrine Biosciences shares in Q2 2026, an estimated $1.38M.
  • Neurocrine Biosciences made up 0.14% of Private Client Services's portfolio in Q2 2026, its #128 holding.
  • Private Client Services first reported a position in Neurocrine Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Private Client Services's Neurocrine Biosciences position peaked at $1.64M in Q1 2026.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Private Client Services's 13F filing for Q2 2026, filed 6 Jul 2026.